Recent Progress in Work on PGD2 Antagonists for Drugs Targeting Allergic Diseases

Author(s): Susumu Mitsumori.

Journal Name: Current Pharmaceutical Design

Volume 10 , Issue 28 , 2004

Become EABM
Become Reviewer

Abstract:

Prostaglandin (PG) D2, the major cyclooxygenase metabolite generated from immunologically stimulated mast cells, is thought to contribute to the pathogenesis of allergic diseases due to its various inflammatory effects. However, the lack of PGD2 (DP) receptor antagonists has limited the study of its essential roles in the disease state. Recent discoveries of several DP receptor antagonists, the development of the mutant mouse and the discovery of a second PGD2 receptor, CRTH2 (chemoattractant receptor-homologousmolecule expressed on Th2 cells) receptor, have revealed the crucial roles of PGD2 and CRTH2 receptors in allergic disorders. This review presents biological evidence that PGD2 plays an essential role in allergy disorders and discusses the therapeutic possibilities of recently reported PGD2 antagonists.

Keywords: pgd2, crth2, bwa868c, s-5751, ramatroban, indometahcin, eosinophil

Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 10
ISSUE: 28
Year: 2004
Page: [3533 - 3538]
Pages: 6
DOI: 10.2174/1381612043382864
Price: $58

Article Metrics

PDF: 6